A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
International Journal Of Cancer
Unseld, Matthias M; Belic, Jelena J; Pierer, Kerstin K; Zhou, Qing Q; Moser, Tina T; Bauer, Raimund R; Piringer, Gudrun G; Gerger, Armin A; Siebenhüner, Alexander A; Speicher, Michael M; Heitzer, Ellen E; Prager, Gerald W GW
Publication Date: 2021-03-15
Variant appearance in text: VWF: 3281T>C; Ile1094Thr